title: Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
abstract: Taxanes (paclitaxel and docetaxel) comprise a class of mitotic inhibitors which considered highly active chemotherapeutic agents against cancer cells, and have become a cornerstone in the treatment of patients with early and advanced breast cancer. Following the initial generation of trials conducted to prove their efficacy, investigators turned to explore which taxane is superior in terms of efficacy, side effects, and quality of life based on head-to-head comparisons of paclitaxel versus docetaxel containing regimens. Moreover, many trials conducted to evaluate the optimal taxane dosing and schedule. This commentary discusses the ERASME 3 trial which compared the quality of life after four courses of doxorubicin combination with either paclitaxel or docetaxel, and also, it reviews all trials compared paclitaxel to docetaxel in both early and metastatic disease settings, in terms of efficacy, dosing, schedule, and toxicity profile.
authors.affiliation: Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-5289, USA.
authors.forename: Sofyan M
authors.initials: SM
authors.lastname: Radaideh
authors.forename: George W
authors.initials: GW
authors.lastname: Sledge
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage*; D043823:Taxoids / Q000008:administration & dosage*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D017239:Paclitaxel